BioAtla Inc.’s recent filing unveils that its Chief Executive Officer SHORT JAY M PHD acquired Company’s shares for reported $0.1 million on Mar 29. In the deal valued at $2.47 per share,40,800 shares were bought. As a result of this transaction, SHORT JAY M PHD now holds 1,412,387 shares worth roughly $ 3.7 million.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Then, Vasquez Christian bought 20,000 shares, generating $47,970 in total proceeds. Upon buying the shares at $2.40, the insider now owns 102,709 shares.
Before that, MCBRINN SYLVIA bought 3,700 shares. BioAtla Inc. shares valued at $30,813 were divested by the Director at a price of $8.33 per share. As a result of the transaction, MCBRINN SYLVIA now holds 9,125 shares, worth roughly $23907.5.
JMP Securities initiated its BioAtla Inc. [BCAB] rating to a Mkt outperform in a research note published on Friday, September 15, 2022; the price target was $17. PT values the company’s stock at a premium of 84.59 to its Friday closing price.
Price Performance Review of BCAB
On Friday, BioAtla Inc. [NASDAQ:BCAB] saw its stock jump 4.38% to $2.62. On the same session, the stock had its day’s lowest price of $2.49, but rose to a high of $2.63. Over the last five days, the stock has gained 7.82%. BioAtla Inc. shares have fallen nearly -68.24% since the year began. Nevertheless, the stocks have fallen -69.92% over the past one year. While a 52-week high of $11.73 was reached on 01/03/23, a 52-week low of $2.23 was recorded on 03/24/23. SMA at 50 days reached $2.80, while 200 days put it at $4.25. A total of 0.52 million shares were traded, compared to the trading of 0.1 million shares in the previous session.
Levels Of Support And Resistance For BCAB Stock
The 24-hour chart illustrates a support level at 2.53, which if violated will result in even more drops to 2.44. On the upside, there is a resistance level at 2.67. A further resistance level may holdings at 2.72. The Relative Strength Index (RSI) on the 14-day chart is 47.76, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 27.27%. Stochastics %K at 59.09% indicates the stock is a holding.
How much short interest is there in BioAtla Inc.?
A steep rise in short interest was recorded in BioAtla Inc. stocks on Aug 14, 2023, growing by 40000.0 shares to a total of 4.73 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 4.69 million shares. There was a rise of 0.85%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 10.78% of the overall stock float, the days-to-cover ratio (short ratio) rose to 22.63.
BioAtla Inc. [BCAB] – Who Are The Largest Shareholders?
In filings from Soleus Capital Management LP, it is revealed that the company now owns 4,321,197 shares, or roughly 9.07% of the outstanding BCAB shares. Additionally, Tang Capital Management LLC increased 1.38% of its stake after which the total value it holdings stand at $10,985,487, while BlackRock Fund Advisors added 234.83% of its stake to hold $8.34 million in the firm. Over the last quarter, The Vanguard Group, Inc. purchased 153,763 shares of BioAtla Inc., while Adage Capital Management LP bought 300,000 shares. At present, Morgan Stanley & Co. LLC is holding 1,678,521 shares valued at $5.02 million. Wasatch Advisors, Inc. owned 1,500,934 shares of the company at the time of its most recent 13F filing, worth $4.49 million.
According to FactSet, BioAtla Inc.’s share price will average $16.33 in the next year, based on opinions of analysts polled by the firm. This is up nearly 517.53 percent from its previous closing price of $2.51. Analysts expect BioAtla Inc. stock to reach the higher price of $25.00, while the lowest price estimate is $12.00. However, 6 analysts have rated BCAB stock as a Buy in their predictions for 2023.